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The yeast mitochondrial DNA (mtDNA) replicase Mip1 has been used as a model to generate five mutations equivalent to POLG mutations
associated with a broad spectrum of diseases in human. All mip1mutations, alone or in combination in cis or in trans, increase mtDNA instability as
measured by petite frequency and EryR mutant accumulation. This phenotype is associated with decreasedMip1 levels in mitochondrial extracts and/
or decreased polymerase activity. We have demonstrated that (1) in the mip1G651S (hG848S) mutant the high mtDNA instability and increased
frequency of point EryR mutations is associated with low Mip1 levels and polymerase activity; (2) in the mip1A692T–E900G (hA889T–hE1143G)
mutant, A692T is the major contributor to mtDNA instability by decreasing polymerase activity, and E900G acts synergistically by decreasing Mip1
levels; (3) in themip1H734Y/mip1G807R (hH932Y/hG1051R) mutant, H734Yis the most deleterious mutation and acts synergistically with G807R as a
result of its dominant character; (4) the mip1E900G (h1143G) mutation is not neutral but results in a temperature-sensitive phenotype associated with
decreased Mip1 levels, a property explaining its synergistic effect with mutations impairing the polymerase activity. Thus, the human E1143G
mutation is not a true polymorphism.
© 2007 Elsevier B.V. All rights reserved.Keywords: POLG; Mutation; Disease; Yeast; mip1 mutant; mtDNA1. Introduction
The mitochondrial genome is replicated by a specific DNA
polymerase called DNA polymerase gamma (pol g) [1].
The catalytic subunit of pol g is phylogenetically related to
the prokaryotic PolA family and its amino acid sequence has
been well conserved during evolution from yeast to human. The
N-terminal part of the protein contains two domains endowed
with dRP-lyase and 3′–5′ exonuclease proofreading activities,
respectively, and is separated from the C-terminal polymerase
domain by a linker region whose length and complexity have
increased from yeast to human. While yeast pol g contains a
single catalytic polypeptide of ∼140 kDa encoded by theMIP1
gene [2], human pol g is a heterotrimer [3] formed by the⁎ Corresponding author. Tel.: +32 010474691; fax: +32 010473872.
E-mail address: foury@fysa.ucl.ac.be (F. Foury).
0925-4439/$ - see front matter © 2007 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbadis.2007.10.002140 kDa catalytic subunit encoded by the POLG gene and two
identical 55 kDa accessory subunits which increase the activity
and processivity of the enzyme.
The first POLG mutations associated with an autosomal
dominant form of progressive external ophtalmoplegia (adPEO)
were reported in 2001 [4]. Six years later more than 80 exonic
mutations have been identified. (Human DNA Polymerase
Gamma Mutation Database at http://dir-apps.niehs.nih.gov/
polg). They are associated with a broad spectrum of mitochon-
drial disorders [5,6] including PEO, myopathy, Parkinsonism,
premature menopause, psychological disorders, ataxia, enceph-
alopathy, and the fatal Alpers syndrome. The affected tissues are
characterized by multiple deletions or depletion of mtDNA.
POLG mutations are often pathogenic as compound heterozy-
gous. However, the mechanisms underlying symptom variabil-
ity are not understood. Moreover, as several POLG mutations
are often simultaneously present in the patients, it is difficult to
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and pathogenic mutations. For instance, the E1143G substitution
identified in 2–3% of the Northern population andmet in healthy
homozygous individuals has been considered as a SNP. How-
ever, it is also very often associated with pathogenic mutations in
cis or in trans [7–11].
The MIP1 gene has previously been used in Saccharomyces
cerevisiae as a model to study pathogenic POLG mutations
[12,13]. Moreover, S. cerevisiae appears as an appropriate or-
ganism to search for genes and mechanisms rescuing the de-
fects generated by deleterious POLG mutations [13,14]. In the
present study five human POLG mutations mapping to the
polymerase domain and associated with a large range of clinical
symptoms, from mild PEO to severe neurological manifesta-
tions and Alpers syndrome, were introduced at the homologous
positions in the MIP1 gene, and compound heterozygous yeast
strains as found in human patients were constructed. The effects
of the mip1 mutations on mtDNA stability and point mtDNA
mutation rate, dominance/recessivity of the phenotypes and
DNA polymerase activity were analysed. We found a good
correlation between mtDNA maintenance in yeast and disease
severity in humans.
2. Materials and methods
2.1. Yeast strains and media
The S. cerevisiae strains used in this work are W303-1B (Matα ade2-1 leu2-
3, 112 ura3-1 trp1-1 his3-11, 15 can1-100), DWM-5A (Matα ade2-1 leu2-3,
112 ura3-1 trp1-1 his3-11, 15 can1-100 mip1::KanR) and DWM-1A, its
isogenic Mata counterpart. DWM-1A and DWM-5A are meiotic segregants
derived from W303 [13].
The diploid DMM was obtained by crossing DWM-5A which harbours
plasmid pFL38MIP1 (see below) and is rho+ with DWM-1A which harbours
plasmid pFL39 (see below) and is rho0. A diploid that has lost pFL39 and
retained pFL38MIP1 was then selected.
YP medium contained 1% Bacto-yeast extract and 2% Bacto-peptone
(Difco). YPA medium was YP medium supplemented with 40 mg/l adenine.
Synthetic defined (SD) medium contained 6.7 g/l yeast nitrogen base without
amino acids (Difco) supplemented with appropriate amino acids and bases.
Synthetic complete (SC) medium contained 6.7 g/l yeast nitrogen base without
amino acids (Difco) and supplemented with 1 g/l of drop-out powder [15]
containing all amino acids except those required for plasmid maintenance.
Carbon substrates were added at the indicated concentration. YPAEG-ery
contained 1% Bacto-yeast extract, 2% Bacto-peptone (Difco), 40 mg/l adenine,
3% ethanol, 3% glycerol, 3 g/l erythromycin (SIGMA) and 25 mM potassium
phospate buffer at pH 6.5.
2.2. Construction of yeast mip1 strains
The mip1 mutations were obtained by site-directed mutagenesis of a MIP1
gene fragment, using the overlap extension technique [16] and after appropriate
restrictions the MIP1 and mip1 alleles were subcloned in the SacI and SalI sites
of the centromeric pFL38 (URA3 marker) or pFL39 (TRP1 marker) plasmids
[17]. The pFL39 plasmid-borne MIP1 and mip1 genes were transformed in the
DWM-5A strain deleted for the MIP1 gene and harbouring the pFL38 plasmid-
borne MIP1 gene to allow mtDNA maintenance. The plasmids were named
pFL39MIP1 (or mip1 followed by the name of the mutation) and pFL38MIP1
(or mip1). In a second step, the pFL39-borne MIP1 or mip1 alleles were
selected through plasmid shuffling using 5-fluoroorotic acid as previously
described [13]. Heteroallelic haploid strains were obtained by transformation
of the pFL39MIP1 or pFL39mip1 plasmid-bearing strains with pFL38-based
plasmids.The plGALmip1 plasmids containing the desired mutation were constructed
by replacing the NotI–NgoMIV fragment of the wild-type MIP1 gene borne by
the plGALMIP1 plasmid [18] with the corresponding mutated fragment. Strain
W303-1B was transformed with plGALZ3 (the empty plasmid), wild-type
plGALMIP1 and plGALmip1 mutant plasmids. The presence of the mip1 mu-
tation was verified by DNA sequencing.
2.3. Nomenclature
DWM-5A strains harbouring mip1 mutations were named as follows. The
mip1 symbol was followed by the residue number preceded by the one-letter-
code symbol of the wild-type amino acid followed by the symbol of the mutant
residue. Thus mip1G651S means mip1 mutant harbouring a mutation from
glycine to serine at position 651 of the amino acid sequence. Heteroallelic strains
harbouring pFL38 plasmid-borne MIP1 and pFL39 plasmid-borne MIP1 (or
mip1) alleles, or empty pFL39 plasmid were designated as MIP1(or mip1)/
MIP1, or MIP1/pFL39 strains. Strain mip1H734Y/mip1G807R was obtained by
transforming the DWM-5A strain harbouring the pFL39 plasmid-borne G807
mutation with the pFL38 plasmid bearing the H734Y mutation. Strain mip1G651S/
mip1E900G was obtained by the same procedure.
2.4. Determination of petite frequency and mtDNA retention
Strains containing MIP1 or mip1 alleles were grown on solid SC medium
supplemented with 2% ethanol at 28 °C to counterselect the petite cells that
could be present in the population. After approximately 60 h, strains were
replica-plated on SC medium supplemented with 2% glucose and grown at
28 °C or 36 °C. After 24 h, strains were replica-plated on SC medium
supplemented with 2% glucose and grown at 28 °C or 36 °C. After 24 h cells
were diluted in water and plated on SC agar plates supplemented with 2%
ethanol and 0.3% glucose at a dilution giving approximately 200 cells per plate.
Petite frequency was defined as the percentage of colonies showing the petite
phenotype after a 5 day-incubation at 28 °C. For each strain at least 4000 clones
were analysed. When 100% petites were obtained, 104 and 105 cells were
directly plated on YP plates supplemented with 3% glycerol to confirm that the
cell population was only composed of petites and did not grow on glycerol.
To determine whether petites had retained mtDNA fragments, the clones in
the DWM-5A background were crossed with mit− mutants, M9-94-4B (Mata
ade1 cox2), M7-40-5B (Mata ade1 cob), M17-162-4B (Mata ade1 cob) and
M9-3-5B (Mata ade1 cox3) [19] as previously described [13]. Mit− mutations
are mtDNA point mutations conferring respiratory deficiency and loss of growth
on a respiratory carbon source [20]. Briefly, for each haploid mip1 mutant, at
least 200 independent petite clones were crossed with the mit− mutants of
opposite mating type on YP plates supplemented with 2% glucose and replica-
plated on YP plates supplemented with 3% glycerol to select rho+ diploid
strains. For the mip1G651S mutant, 200 independent clones were crossed with
mit− mutants immediately after isolation of the mutant strain.
2.5. Frequency of erythromycin resistant (EryR) mutants
Two independent series of 10 independent colonies grown on YP plates
supplemented with 3% glycerol were inoculated in 2.5 ml cultures of YPA
supplemented with 3% glycerol. After 48 h at 28 °C, 1.5 ml of each culture,
corresponding to 6–8×107 cells, were plated on YPAEG-ery medium and
incubated at 28 °C for 9 days. A small aliquot of each culture was spread for
single colonies on YP plates supplemented with 3% glycerol to determine the
number of rho+ cells initially present in the cultures. The mutation frequency
was calculated as the number of EryR colonies per 108 rho+ cells. For
heteroallelic strains containing both pFL39- and pFL38-derived plasmids, the
same test was carried out, except that colonies were grown on SD plates
supplemented with 2% glucose and then inoculated in 2.5-ml cultures of SC
medium supplemented with 2% ethanol to avoid loss of one plasmid.
2.6. Southern hybridisation
Cells pre-grown on SC medium supplemented with 2% ethanol (except for
mutant mip1G651S which was supplemented with 2% glucose) were inoculated
Fig. 1. Position and conservation of mutated amino acids associated with mitochondrial diseases in several DNA polymerases gamma and E. coli DNA polymerase
I. A. Linear representation of human pol g and Mip1 polymerases. I, II and III refer to the ExoI, ExoII, and ExoIII conserved motifs of the 3′–5′ exonuclease domain,
and A, B and C refer to the polA, polB and polC conserved motifs of the polymerase domain. B. Multiple amino acid alignment of regions encompassing the mutated
residues. Numbers refer to the position of the residues in the amino acid sequence. Mutated residues are in bold characters and underlined in H. sapiens and
S. cerevisiae. Alignment of DNA was carried out by using CLUSTALW program [37].
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Total DNA was extracted by standard procedures, digested with EcoRI, and
subjected to electrophoresis in a 0.8% agarose gel. The TRP1 alleles harboured
by the pFL39MIP1 plasmid and the genome are contained within DNA
fragments of 4.8 and 1.45 kb, respectively. Hybridisation was performed by
standard procedures with the TRP1 gene as a probe using [α-32P]dCTP and the
kit ‘Rediprime II DNA Labeling System’ (GE Healthcare). The TRP1 probe was
obtained by BglII digestion of the pFL39 plasmid. The signals were quantified
after a 15-min exposure with a PhosphorImager (Molecular Dynamics).
2.7. DNA polymerase assay
Mitochondrial extracts were obtained from strain W303-1B overexpressing
the MIP1 (mip1) alleles under the control of the GAL1 promoter in a 2%
galactose-containing SC medium for 15 h at 30 °C as previously reported [18].
The W303-1B strain harbouring the empty GALZ3 plasmid was taken as the
negative control. The gap-filling activity assay was carried out in a reaction
mixture containing 20 mM Tris–HCl pH 8.0, 5 mM dithiothreitol, 50 mMTable 1
Relevant pathologies, human POLG mutations and yeast mip1 equivalents studied i
Human POLG mutations Equivalent mip
Allele 1 a Allele 2 a Allele 1
G848S T251I–P587L G651S
G848S A467T G651S
G848S W748S–E1143G G651S
A889T–E1143G Wt c A692T–E900G
A889T R579W A692T
H932Y G1051R H734Y
a Alleles 1 and 2 are borne in trans by different chromosomes.
b NC, not conserved.
c Wt, wild-type.MgCl2, 25 μM each dATP, dCTP, dGTP, 6 μM [
3H]-dTTP, 150 μg/ml calf
thymus activated DNA and the mitochondrial extract. Samples were taken after
6 min of incubation at 30 °C. The activity was expressed in nmol dTTP
incorporated into trichloroacetic precipitable material per h and per mg protein
present in the extract or was reported to an arbitrary amount of Mip1 (100 for the
wild-type).
3. Results
3.1. Choice of POLG mutations and construction of mip1
mutants
Positions of the mutations studied in this work are shown in
Fig. 1A.
The recessive G848S mutation which affects a conserved
glycine residue upstream of motif polA (Fig. 1B) in then this work
1 mutations Pathology
Allele 2
NCb PEO [25,26]
NC Alpers [9,21,23,24]
NC-E900G Alpers [22,23]
Wt Tremor or adPEO/neuropathy [8]
NC PEO/neuropathy [27]
G807R PEO/neuropathy [28]
Fig. 2. Estimation of the copy number of pFL39-borne MIP1 (mip1) genes in
wild-type and mutants. The MIP1 (mip1) genes were borne by the pFL39
plasmid. The standard deviation of the ratio of the plasmid to genomic DNAwas
in the range of 0.1–0.3. Southern blotting was performed as described in
Materials and methods.
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from PEO to the Alpers syndrome, according to the associated
mutations in trans [9,21–26] (Table 1). The A889T mutation
affects a conserved residue immediately upstream of motif polA
(Fig. 1B). This mutation associated in cis with the SNP E1143G
(Fig. 1B) has been reported as dominant in two brothers with
PEO and severe neurological manifestations [8] (Table 1). Their
mother and two grand-uncles, obligate mutation carriers,
showed only tremors, suggesting that genetic or environmental
factors modulate the severity of the phenotype. The A889T
mutation has also been reported to be associated in transwith the
R579W mutation in a brother and a sister with PEO, sensory
ataxia, areflexia, and gastrointestinal dysmotility [27]. Since in
this case parents were healthy A889Tseems, when alone, to be a
recessive mutation. However, since one POLG mutation in
different families and individuals may cause different kinds of
disorders it cannot be excluded that A889T alone is dominant.
Nevertheless, the most likely hypothesis is that E1143G
modifies the pathogenic effect of A889T.
The H932Y mutation affects a strictly conserved residue
slightly upstream of motif polB (Fig. 1B). The G1051R
mutation affects a residue located between motifs polB and
polC within a region poorly conserved in prokaryotic DNA
polymerases (Fig. 1B). H932Y/G1051R compound heterozy-
gous patients developed a complex syndrome including PEO,
polyneuropathy, ataxia, hearing loss and psychiatric disorders
[28] (Table 1).
The equivalent mip1 mutations G651S (hG848S), A692T
(hA889T), H734Y (hH932Y), G807R (hG1051R) and E900G
(hE1143G) obtained by site-directed mutagenesis (Fig. 1A)
were introduced in the MIP1 gene borne by a low copy
centromeric vector and the mip1 alleles were cloned in a yeast
strain whose chromosomal MIP1 gene was deleted. The MIP1
allele used in this work is found in several commonly used
laboratory strains including the S288c reference strain and
W303. It contains an alanine at position 661. However, T661 is a
strictly conserved residue from fungi to human, and all natural
S. cerevisiae strains contain a threonine at this position. We have
recently shown that the T661A substitution is a mutation
increasing mtDNA instability in a temperature-dependent
manner [29]. Here, the choice of the A661 context is based on
two previous reports on the effect of pathogenic POLG
mutations which were using the Ala661-containing MIP1 gene
as a model [12,13]. In the last section we present a comparison of
the mutant phenotypes obtained in the A661 and T661 contexts.
Southern blotting experiments were performed to estimate
the average copy number of pFL39 plasmid-borneMIP1 (mip1)
gene. Even though it was not excluded that mutants mip1G651S
and mip1H734Y contained on average slightly more than one
copy per cell, chromosomal and plasmid DNAs were grossly in
stoichiometric amounts in all mutants (Fig. 2), indicating that
the copy number of the mip1 alleles was not influenced by their
presence on a centromeric vector.Fig. 3. Oxidative growth phenotype of wild-type,mip1 and heteroallelic strains. Cell g
YP medium supplemented with 2% ethanol at 36 °C (cells were unable to grow on et
cells were spotted. Pictures were taken after 4 days. A. mip1 mutants at 28 °C. B. m3.2. Effect of mip1 mutations on oxidative growth phenotype
The analysis of cellular growth on an obligatory respiratory
carbon source such as ethanol or glycerol is a simple method to
test mitochondrial function. All mutants except mip1G651S were
able to grow on ethanol at 28 °C (Fig. 3A). Whereas mutants
mip1G807R and mip1E900G were growing like the wild-type,
cellular growth of mutants mip1A692T and mip1H734Y, and to a
greater extent that of mutant mip1A692T–E900G, was impaired. In
all mutants the growth defect was more pronounced at 36 °C
(Fig. 3B).
3.3. Effect of single mip1 mutations on petite accumulation
The patients harbouring the mutations studied here present
multiple deletions or depletion of mtDNA.While in human cells
deleted and intact mtDNA molecules are coexisting, S.
cerevisiae has the unique property to produce cells with
homoplasmic deleted mtDNA molecules, which are referred
to as petites or rho− mutants [30]. These mutants do not grow
on respiratory carbon sources but they can grow on glucose
thanks to the energy produced by fermentation. In all mip1
mutants the frequency of petites was increased at 28 °C, being
quite low in mip1E900G (6%), moderate in mip1G807R (25%) and
high in mip1A692T and mip1H734Y (80 and 99%, respectively)
(Table 2). In all strains petite frequency was increased at 36 °C.
The temperature-sensitive trait was specially marked for the
G807R and E900G mutations, which yielded 99% and 92%
petites, respectively (Table 2). No rho+ colony was obtained
for mutant mip1G651S, suggesting that mtDNA maintenance
was incompatible with the G651S mutation. Petite cells either
contain amplified mtDNA fragments mapping to various
positions of the mtDNA molecule, and are referred here to as
rho−, or are completely devoid of mtDNA and referred to as
rho0. To distinguish between rho− and rho0 clones we used a
genetic test based on the capacity of the mtDNA fragmentsrowth was tested on SC medium supplemented with 2% ethanol at 28 °C, and on
hanol supplemented SC medium at 36 °C). For each strain, 105, 104, 103 and 102
ip1 mutants at 36 °C. C. Heteroallelic haploid strains at 28 °C.
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Table 2
Petite and EryR mutant frequency in mip1 mutants
Haploid
strain a
28 °C 36 °C EryR mutant
frequency b
%
petites c
%
rho0 d
%
petites
%
rho0
EryR
(×108)
Fold
increase
MIP1 2.7±0.3 13 21.0±2.4 37 6.0±0.4 1.0
mip1G651S 100±0 100 – – NDe –
mip1A692T 80.3±1.7 86 99.7±0.1 100 22.2±2.7 3.7
mip1H734Y 99.7±0.1 94 100±0 100 ND –
mip1G807R 25.5±2.8 55 99.2±0.2 99 61.6±6.1 10.2
mip1E900G 6.0±0.6 33 91.7±3.9 88 11.6±1.3 1.9
mip1A692T–E900G 96.6±1.5 96 100±0 100 20.4±1.3 3.4
a The DWM-5A strain contains the MIP1 (or mip1) gene borne by the pFL39
plasmid.
b The frequency of EryR mutants was calculated as the ratio of the number of
EryR mutants to the number of rho+ cells plated on the Petri dish. The ‘fold
increase’ was calculated by normalization of the wild-type MIP1 strain relative
frequency to 1.
c In this work ‘petites’ designates both rho− clones with mtDNA deletions and
rho0 clones. For each MIP1 (mip1) strain the data are averages obtained from
three independent experiments and two independent transformants.
d Although not formally demonstrated a petite mutant which does not restore
any of the four mit-tester strains is referred to as rho0. Rho0 frequencies are
calculated as the ratio of the number of rho0 to the number of petite cells.
e ND, not determined.
Table 3
Petite mutant frequency in heteroallelic diploid strains
Diploid strains % petites at 28 °C
MIP1/MIP1 0.8±0.1
MIP1/pFL39 2.1±0.1
MIP1/mip1G651S 1.8±0.2
MIP1/mip1A692T 2.6±0.1
MIP1/mip1H734Y 7.4±0.9
MIP1/mip1G807R 1.6±0.1
MIP1/mip1E900G 0.8±0.1
MIP1/mip1A692T–E900G 2.5±0.1
mip1H734Y/mip1G807R 83.9±2.7
mip1G651S/mip1E900G 6.9±0.5
The DWM-5A strain contains pFL38 and pFL39 plasmid-borneMIP1 and mip1
genes, respectively, as reported under Materials and methods. Experimental
conditions were as described in Table 2.
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mologous recombination [31]. The mit− mutations were
selected in the cox2, cox3 and cob genes, because these
correspond to the most frequently retained loci in rho− mutants
[32]. Absence of restoration of these mit− mutants to wild-type
by a large number of petite clones provides good evidence that
the mip1 mutation leads to a total loss of mtDNA. Our data
show that there was a good correlation between petite frequency
and the loss of mtDNA (Table 2). In particular, they strongly
suggest that the mip1G651S mutant is not able to maintain a
fragment of mtDNA, implying a severe defect in mtDNA
replication.
3.4. Effect of single mip1 mutations on EryR mutant frequency
The fidelity of mtDNA replication was estimated by the
frequency of erythromycin (EryR) mutants. EryR mutations are
caused by mutations in the mtDNA 21S rRNA gene (nucleo-
tides 59965−59967 on the mtDNA map in SGD database http://
www.yeastgenome.org/) [33]. All types of substitutions can be
obtained. An increased frequency of EryR mutants was
observed in all tested mip1 mutants, but there was no
relationship between EryR and petite mutant frequencies
(Table 2).
3.5. Dominance/recessivity of mip1 mutations
Dominance/recessivity of each mip1 mutation was deter-
mined in diploids in which both chromosomalMIP1 genes were
deleted and replaced by a pFL38-borne wild-type MIP1 gene
and a pFL39-borne wild-type MIP1 or mutant mip1 gene
(Table 3). A diploid strain containing two copies of the MIP1gene produced less than 1% petites at 28 °C. When one MIP1
copy was replaced by the empty plasmid (pFL39), the petite
frequency was two-fold higher at 28 °C and further increased at
36 °C. Petite accumulation in the presence of a single copy of
MIP1 is a sign of haploinsufficiency suggesting that Mip1 is a
limiting factor in mtDNA replication.
At 28 °C, the percentage of petites was similar in the
MIP1/mip1E900G and MIP1/MIP1 strains, indicating that the
mip1E900G allele is functional. All other MIP1/mip1 strains
showed haploinsufficiency, to various extents, suggesting that
the mip1 alleles in diploids are poorly functional. In the MIP1/
mip1H734Y strain petite accumulation was significantly higher
(7.4%) than in a strain bearing a single copy of wild-type MIP1
(2.1%), indicating that the mip1H734Y allele is dominant
(Table 3). In all strains EryR mutant accumulation was recessive
(data not shown).
3.6. Functional interactions of mip1 mutations in cis or in trans
In order to simulate human situations, mutants carrying
several mutations in cis or in trans were constructed both in
diploid (Table 3) and haploid states (data not shown). In the
latter context, the frequency of rho0 clones could be determined
in crosses with mit− mutants. The presence of the E900G
mutation in cis with the A692T mutation exacerbated the
mtDNA defects produced by the A692T mutation, but did not
further increase the frequency of EryR mutants (Table 2). No
difference was observed between the MIP1/mip1A692T and
MIP1/mip1A692T−E900G diploid strains (Table 3), leading to the
conclusion that the presence of the E900G mutation in cis does
not result in a dominant phenotype, as suggested in human for
the E1143G substitution associated in cis with the A889T
mutation.
When two plasmid-borne MIP1 (or mip1) genes were
introduced into a haploid instead of a diploid strain, petite
frequency was quite similar (compare MIP1/MIP1, mip1/
pFL39, MIP1/mip1G807R, MIP1/mip1H734Y in Tables 3 and 4).
Strains mip1H734Y/mip1H734Y and mip1G807R/mip1G807R pro-
duced 97.8% and 8.7% petites, respectively (Table 4). Petite
accumulation in the heteroallelic haploid mip1H734Y/mip1G807R
strain reached 70.7% (versus 83.9 in a diploid strain in Table 3),
Table 4
Synergistic effects of the G807R and H734Y mutations
Haploid heteroallelic
strain
% petites % rho0 EryR mutant
frequency (×108)
MIP1/MIP1 1.0±0.1 11 2.2±0.4
MIP1/pFL39 2.7±0.3 24 8.0±0.8
MIP1/mip1G807R 1.7±0.3 21 6.2±0.5
MIP1/mip1H734Y 6.7±0.7 22 3.5±0.3
mip1H734Y/mip1H734Y 97.8±0.2 91 ND
mip1G807R/mip1G807R 8.7±1.8 29 48.6±3.6
mip1H734Y/mip1G807R 70.7±4.8 82 41.2±4.4
The DWM-5A strain contains pFL38 and pFL39 plasmid-borneMIP1 and mip1
genes, respectively, as reported under Materials and methods. Experimental
conditions were as described in Table 2. ND, not determined.
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indicating that the mild G807R mutation was unable to
compensate for the deleterious effects of the H734Y mutation.
In agreement with these data the mip1H734Y/mip1G807R strain
grew on ethanol-containing medium slightly better than the
mip1H734Y/mip1H734Y strain but more slowly than the MIP1/
pFL39 and MIP1/mip1G807R strains (Fig. 2C). The dominant
trait of the H734Y mutation was thus confirmed, providing
support to the view that the human equivalent H932Y is
dominant. The frequency of EryR mutants was hardly
decreased in the compound heterozygous strain compared to
the mip1G807R/mip1G807R strain (Table 4), implying that the
contribution of Mip1H734Y polymerase to the fidelity of
mtDNA replication was small.
In haploid or diploid mip1E900G/mip1G651S strains petite
frequency reached 6−6.9%, a percentage higher than in the
strain homozygous for the E900G mutation (∼2%) and similar
to that of a strain bearing a single copy of the E900G mutation,Fig. 4. Estimation of wild-type and mutant Mip1 levels in mitochondrial extracts. Th
PAGE in a 7% polyacrylamide gel and Mip1 was detected by Western blotting using
solubilisation buffer were loaded onto the gel and the intensity of the signal was co
expressed under the control of the GAL1 promoter. The wild-type mitochondrial extra
A. Mip1 was expressed from the chromosomal MIP1 gene in cells containing the em
from 0.25 to 1 μl of extract. B and C. The levels of Mip1A692T–E900G, Mip1G807R, M
control of the GAL1 promoter were estimated by using a standard curve from 1 to 4supporting further the hypothesis that mip1G651S behaves like a
null allele.
3.7. Levels and gap-filling activity of wild-type and mutant
Mip1p
POLG mutations in the polymerase domain can be ranged
into two broad classes. a) Mutations altering protein conforma-
tion, as a result of an intrinsic folding defect or an alteration of
protein interactions with the DNA substrate. b) Mutations
impairing polymerase activity, and altering, or not, the protein
structure.
Mip1 is naturally poorly expressed and gives a very faint
signal in Western blots (Fig. 4A). Therefore, soluble mitochon-
drial extracts were prepared from cells overexpressing theMIP1
gene from the strong inducible GAL1 promoter. We first
verified that MIP1 gene expression was similar in all strains
(data not shown). However, in all mutants, the amount of Mip1
in the mitochondrial extracts was lower than that in the wild-
type (Fig. 4B and C, and Table 5), but to various extents.
Whereas the amounts of Mip1A692T were quite comparable to
that of the wild-type, those of Mip1G651S, Mip1G807R and
Mip1A692T−E900G were very low (b10% of wild-type Mip1),
and those of Mip1H734Y and Mip1E900G were substantially
reduced (Fig. 4B and C and Table 5). By comparison, the
extracts of a strain expressing the chromosomal MIP1 gene
contained 1.5−2% of the amount present in the overproducing
wild-type strain (Table 5).
Gap-filling activity measures the capacity of incorporating
nucleotides into short gaps of excess duplex DNA and is thus
independent of the processivity of the enzyme. A decrease in
this activity reflects mainly a defect in catalysis or a decrease ine extracts prepared as reported in Materials and methods were subjected to SDS-
a polyclonal antibody raised against Mip1. For each strain, 30 μl of extract in the
mpared to that obtained by increasing amounts of the standard wild-type Mip1
ct contained 2 mg/ml protein. Western blots A, B and C were run independently.
pty GALZ3 plasmid and its level was estimated by using a standard Mip1 curve
ip1G551S, Mip1H734Y and Mip1, Mip1E900G and Mip1A692T expressed under the
μl (B) or 1 to 30 μl (C).
Table 6
Petite and EryR mutant frequency in mip1 mutants in the T661 context
Haploid strain % petites EryR mutant frequency
28 °C 36 °C EryR (×108) Fold increase
MIP1 0.8±0.1 1.0±0.1 2.4±0.4 1.0
mip1G651S 45.7±4.9 99.7±0.2 37.3±4.7 15.5
mip1A692T 17.1±1.6 40.1±0.3 3.2±0.2 1.3
mip1H734Y 97.8±0.4 98.8±0.3 ND –
mip1G807R 2.1±0.2 9.5±0.8 7.9±0.8 3.3
mip1E900G 1.3±0.1 5.0±0.1 3.8±0.2 1.6
mip1A692T–E900G 35.5±2.0 78.1±3.2 3.3±0.2 1.4
All experimental conditions were the same as in Table 2 except that a threonine
instead of an alanine is present at position 661 of the Mip1 amino acid sequence.
ND, not determined.
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amount of Mip1 protein in the assay. Gap-filling activities of
Mip1E900G and Mip1G807R were not modified (Mip1E900G) or
close (Mip1G807R) to that of the wild-type (Table 5). Together
with the observation that in these mutants Mip1 levels are
decreased, these data suggest that the mtDNA replication
defects of these mutants mainly result from limiting amounts of
Mip1. In contrast, the activity of Mip1A692T reached only 30%
of that of the wild-type. Since Mip1A692T levels were close to
that of wild-type, it could be concluded that the mtDNA
replication defects produced by the A692T mutation are mainly
caused by an intrinsic defect in the polymerase activity of the
enzyme. The gap-filling activity of Mip1A692T−E900G was
similar to that of Mip1A692T (Table 5). Since the major effect
of the E900G mutation in the presence of the A692T mutation
was a dramatic decrease of Mip1 levels in the extracts (Fig. 4
and Table 5), the low mtDNA replication capacity of the
mip1A692T−E900G mutant was better explained by the cumulative
effects of low polymerase activity caused by A692T and low
protein levels caused by E900G. The Mip1G651S, and to a lesser
extent, Mip1H734Y polymerases combined decreased gap-filling
activity and lower expression.
3.8. Comparison of the MIP1T661and MIP1A661 alleles
As mentioned earlier in this paper the T661A substitution
present in the MIP1 gene used in this work decreases mtDNA
stability of ‘wild-type’ laboratory strains [29]. To determine the
influence of the T661A substitution, the mutant phenotypes
were compared in the A661 and T661 contexts (Tables 2 and 6).
Although mutability and temperature sensitivity were remark-
ably more pronounced in the presence of A661, there was no
fundamental discrepancy in the two genetic contexts. (1) G651S
and H734Y strongly increased petite frequency; (2) E900G
increased petite frequency approximately by two-fold; (3) A692TTable 5
Mip1 levels and gap-filling activity in mitochondrial extracts
Strain Mip1 level a (% wt) Specific gap-filling b activity (% wt)
GALMip1 100 100
GALZ3 c 1.5–2.0 100–130 d
G651S 7–10 42–55
A692T 100 29–30
H734Y 10–20 30–46
G807R 9–15 65–86
E900G 20–50 107–139 d
A692T–E900G 3–6 30–40
a The amounts of Mip1 in the mitochondrial extracts were estimated by using
Mip1 standard curves as reported in Fig. 4. For each strain the extreme ranges
obtained for mitochondrial extracts from different cultures are indicated.
b Wild-type GALMip1 incorporates 456±50 nmol dTTP/mg extract protein/
h into trichloroacetic acid precipitable material. The gap-filling activity was
normalized to the same amount of Mip1 for all strains and expressed as a
percentage of wild-type activity (100%).
c GALZ3 corresponds to the wild-type strain containing the empty GALZ3
plasmid.
d These values are not significantly different from those reported for
GALMip1.and G807R increased petite frequency at an intermediate level;
(4) E900G behaved as a phenotypic modifier of A692T in cis; (5)
in all mutants the frequency of point EryR mutants was increased.
(6) The dominant or recessive character of the mutations, and more
specifically H734Y dominance, were not influenced by the A661
or T661 context (data not shown). However, the haploinsuffi-
ciency observed in the presence of a singleMIP1 copy instead of
two had disappeared in the T661 context (data not shown).
Moreover, whereas in mip1G651S mutant mtDNA was not
maintained in the A661 context, preventing further analysis of
point mutant accumulation, in the T661 context almost half of the
cell population was still rho+ at 28 °C and showed an increased
rate of EryR point mutations (Table 6).
4. Discussion
The question addressed in this work was: Is S. cerevisiae a
good model to determine the effect of each individual mutation
in patients harbouring several POLG mutations in cis or as
compound heterozygous? Indeed, except in the case of
dominant PEO, the patients often carry more than one POLG
mutation in cis or in trans, and thus the specific contribution of
each mutation to the disease cannot easily be established.
In this work we have shown that all the single substitution
mip1 mutations studied here cause mtDNA defects, increasing
the frequency of deletions and in some cases the frequency of
point mutations. We have found a good correlation between
decreased cellular oxidative growth, petite frequency and loss
of mtDNA. In contrast, there is no clear relationship between
petite and point mutation frequencies. Although the two MIP1
alleles used in our study, T661 and A661, confer very different
levels in mtDNA instability, the classification of these
mutations is similar. From the highest to lowest severity the
ranking is G651S (hG848S) and H734Y (hH932Y)NA692T
(hA889T)NG807R (hG1051R)NE900G (hE1143G).
The extreme severity of the G651S mutation fits with the
observation that patients who compound heterozygous for
G848S and A467T, or G848S and W748S-E1143G mutations,
present with the fatal Alpers syndrome [22–24].
Whereas the relative contribution of mutations H932Y and
G1051R in trans could not be established in the patients,
comparison of the severity of the yeast H734Y and G807R
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disease is H932Y, and moreover, our data show a strong
synergistic deleterious effect of the two mutations associated in
trans. In addition, the family history shows that individuals
heterozygous for the H932Y mutation were developing mild
symptoms or were asymptomatic, but conclusions were
obscured by the presence of migraines and psychiatric disorders
of unknown origin in several members of the family [28]. Our
data in yeast have demonstrated that both in the A661 and T661
contexts, H734Y is dominant, suggesting that heterozygosity
for H932Y has potential to cause symptoms in human.
Because A889T, the human equivalent of yeast A692T, was
associated either with R579W in trans [27] or with E1143G in
cis (the equivalent of yeast E900G), it was not possible to de-
termine the individual contribution of A889T to the disease. Our
data in yeast show that, when alone, A692T increases mtDNA
instability significantly and E900G has a very mild phenotype.
Therefore, it can be concluded that A889T significantly contri-
butes to the disease. However, the association of E900G and
A692T in cis has a strong deleterious synergistic effect result-
ing probably from the combination of a folding defect pro-
duced by E900G which decreases pol g levels and an intrinsic
polymerisation defect produced by A692T. Therefore, it is
possible that in humans symptoms are worsened by E1143G.
Since in the carrier family the A692T–E900G mutations were
dominant, though to different severity levels, it was concluded
that E900G could be responsible for the dominant character.
Our data show that the very weak dominant phenotype de-
tected in the mip1A692T mutant is not further increased in the
mip1A692T–E900G mutant, demonstrating that E900G does not
confer a dominant phenotype and suggesting that the strong
dominant phenotype observed in some members of the family
[8] was not caused by E1143G but more likely by other factors
interacting with POLG.
As discussed above our data show that E900G is not a silent
mutation. When alone, it confers a strong temperature-sensitive
phenotype in the A661 context, and even in the T661 context, a
5-fold increase in petite frequency is observed at 36 °C. This
temperature-sensitive trait associated with the observation that
Mip1 levels are decreased inmitochondrial extracts suggests that
the E900G mutation acts on Mip1 structure. Thus, the
deleterious synergistic effect of E900G mutation would be
better explained by the combination of decreased amounts of
protein caused by E900G and decreased polymerase activity
caused by A692T. In contrast with these data, it has been
reported that when associated with theW748S mutation in cis as
found in patients, E1143G partially rescues the deleterious
defects of the W748S mutation in vitro by improving the
catalytic activity and the affinity for DNA of the mutant protein
[34]. As this is the case in yeast for E900G associated with
A692T, the E1143G substitution increases instability ofW748S-
E1143G pol g, and thus its unfolding propensity at body
temperature. However, we do not think that these data, obtained
in yeast and human for different mutations, are necessarily
contradictory. They rather suggest that the effect of E1143G, by
modifying protein structure, may depend on the secondmutation
it is combined with. The effect of the combination of the W748Sand E1143G equivalents in yeast could not be studied since
Trp748 is not conserved in Mip1.
A matter of debate is whether accumulation of point
mutations in mtDNA contributes to the disease. It has been
postulated that point mutations near direct repeats are an early
event in PEO which contributes to the formation of deletions
[35]. On the other hand, muscle sample analysis of PEO patients
with enhanced levels of point mutations and deletions [36]
revealed that in young patients deletions were observed before
any point mutation accumulation (point mutations occurring in
an age-dependent manner). In addition, point mutation overload
was specifically observed in the control region of mtDNA,
whereas deletion break-points were mainly produced close to
homopolymeric runs, suggesting that replication stalling was the
primary cause of deletions [36]. Moreover, no point mutations
were found in 136 single COX-negative fibres from biopsies of
PEO patients harbouring multiple deletions [26]. It was
concluded that the clonal expansion of mtDNA deletions
accounts solely for the pathogenesis of mitochondrial diseases.
The frequency of point EryR mutations is increased in all mip1
mutants, suggesting that fidelity of mtDNA replication is
decreased or mutation fixation is increased. However, each
mutant behaves differently, with no correlation between the
frequency of point mutations and deletions. The mip1A692T
mutant produces a greater number of petites than the mip1G807R
mutant, but a smaller number of EryR mutations. The percentage
of petites is substantially increased in the mip1A692T–E900G
mutant, compared to the single substitution mip1A692T mutant,
but the frequency of EryR mutants is unchanged. The mip1H734Y
allele is dominant with regards to petite frequency, but it is
recessive for EryR mutant frequency. This suggests that mtDNA
instability is caused in general by different mechanisms from
those producing single point mutation, although it cannot be
excluded that increased point mutability could be involved for
some POLGmutations. For example, the G651S mutation in the
T661 context leads to the highest accumulation of rho− clones
and point mutations. A better understanding of the role of the
mutated pol g residue and mechanisms leading to mtDNA
instability will allow to establish the relationship between point
mutations and deletions in the different mutants.
Finally, we would like to discuss reasons for using A661 or
T661 alleles. The present work has been centred on the A661
allele in order to facilitate comparisons with two previous works
on POLG mutations [12,13], and also because the reference S.
cerevisiae strain used for large scale functional analyses contains
Ala661. In all mutants, except mip1H734Y, mtDNA defects were
dramatically increased in the A661 background. This was
particularly marked for the G651S and E900G mutations. When
borne by the A661 allele the G651S mutation results in a null
rho0 phenotype whereas in the T661 context it allows mtDNA
maintenance in almost half of the cells at the permissive
temperature. Similarly, the temperature-sensitive properties of
the E900G mutation in the A661 context are remarkably less
pronounced in the T661 context. Thus, although the A661 allele
may introduce bias in interpretation of the data, it can also
emphasize subtle phenotypes and facilitate a systematic search
for phenotypic suppressors.
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